Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis

被引:14
作者
Hope, WW
Warn, PA
Sharp, A
Reed, P
Keevil, B
Louie, A
Denning, DW
Drusano, GL
机构
[1] Univ Manchester, Dept Med, Manchester M13 9PL, Lancs, England
[2] Hope Hosp, Dept Biochem, Manchester, Lancs, England
[3] Wythenshawe Hosp, Dept Biochem, Manchester M23 9LT, Lancs, England
[4] Ordway Res Inst, Albany, NY USA
关键词
D O I
10.1086/432069
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmacodynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine (5FC) by use of the Greco model of drug interaction. The combination was additive, meaning that the experimental effect did not deviate in a statistically significant manner from the null reference model (or additive surface) of the combined effect. From a clinical perspective, the addition of 5FC to a regimen of AmB may enable the near-maximum effect to be reached in circumstances in which the administration of a given dose of AmB alone produces a submaximum effect but an increase in the dose is not possible, because of dose-related toxicity. Our methods provide a way in which some of the complex issues surrounding antifungal combination treatment can be addressed.
引用
收藏
页码:673 / 680
页数:8
相关论文
共 29 条
  • [1] A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
    AbeleHorn, M
    Kopp, A
    Sternberg, U
    Ohly, A
    Dauber, A
    Russwurm, W
    Buchinger, W
    Nagengast, O
    Emmerling, P
    [J]. INFECTION, 1996, 24 (06) : 426 - 432
  • [2] In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model
    Andes, D
    van Ogtrop, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 938 - 942
  • [3] Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
    Andes, D
    Stamsted, T
    Conklin, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 922 - 926
  • [4] DARGENIO DZ, 1997, ADAPT 2 PROGRAM SIMU
  • [5] In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach
    Dorsthorst, DTAT
    Verweij, PE
    Meletiadis, J
    Bergervoet, M
    Punt, NC
    Meis, JFGM
    Mouton, JW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) : 2982 - 2989
  • [6] Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
    Drusano, GL
    D'Argenio, DZ
    Symonds, W
    Bilello, PA
    McDowell, J
    Sadler, B
    Bye, A
    Bilello, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2153 - 2159
  • [7] Eilard T, 1976, J Antimicrob Chemother, V2, P239, DOI 10.1093/jac/2.3.239
  • [8] GRECO WR, 1995, PHARMACOL REV, V47, P331
  • [9] Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits
    Groll, AH
    Mickiene, D
    Petraitis, V
    Petraitiene, R
    Alfaro, RM
    King, C
    Piscitelli, SC
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) : 3917 - 3925
  • [10] Attributable mortality of nosocomial candidemia, revisited
    Gudlaugsson, O
    Gillespie, S
    Lee, K
    Berg, JV
    Hu, JF
    Messer, S
    Herwaldt, L
    Pfaller, M
    Diekema, D
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) : 1172 - 1177